About Oncoscope


Oncoscope was founded in June 2006 to develop clinical applications of discoveries in the field of optical imaging pioneered by Dr. Adam Wax at the Department of Biomedical Engineering at Duke University.  This technology, known as Angle-resolved Low Coherence Interferometry (a/LCI) arose from work supported by grants from the National Cancer Institute, the National Science Foundation, and the Wallace H. Coulter Foundation.

In 2007, Oncoscope received exclusive, worldwide license rights from Duke University to a/LCI optical imaging technology and began developing clinical prototypes.  Work continued at Duke University including animal and human clinical testing of a/LCI in esophageal tissue.  The results of the first pilot study of 30 patients were presented in May 2009 at Digestive Disease Week in Chicago, IL.  Read more about a/LCI on our Technology page.

Oncoscope completed a clinical study involving 175 patients funded by an NIH SBIR grant in 2011.  The study was conducted at The Center for Esophageal Diseases & Swallowing at the University of North Carolina, Chapel Hill under the direction of Dr. Nicholas J. Shaheen and the Thompson Cancer Survival Center in Knoxville, TN under the direction of Dr. Bergein F. Overholt.  Results from these studies were published in January 2011 in Gastroenterology.